ERBC

What ERBC does

ERBC (European Research Biology Center) is a privately held preclinical Contract Research Organization headquartered in Baugy, France, operating six integrated sites across France and Italy. Formed in November 2019 from the combination of CERB and RTC (Italy), ERBC has since executed a programmatic M&A strategy, acquiring Bioprim (2020), Novaxia (2022), Oncofactory (2023), and Voxcan (2023), before unifying all entities under a single ERBC brand in March 2025. The company delivers GLP and non-GLP toxicology, safety pharmacology, bioanalysis, histopathology, PK/PD studies, NHP supply, and translational research to pharmaceutical, biotechnology, chemical, cosmetic, and medical device sponsors globally.

Its service portfolio is built around vertically integrated capabilities spanning early discovery through regulatory toxicology, supported by BSL2/BSL3 containment laboratories, integrated NHP breeding and quarantine, digital pathology, proprietary non-invasive telemetry, and avian-embryo oncology models. Proprietary or branded platforms include AVI-PDX (avian embryo PDX), DECRO (non-invasive jacket telemetry), Patholytix (digital pathology), CellDX/PDX models, and GENESIS (scientific due diligence advisory). ERBC holds full AAALAC International accreditation across all sites (March 2026), Cofrac GLP Grade A at Baugy (November 2024), and GCP compliance for its clinical central laboratory, providing a regulatory moat in regulated preclinical work.

ERBC operates a sales-led enterprise GTM model with alliance management directors who consult on study design and issue tailored proposals specifying timelines and costs. Revenue is generated through project-based contract research services billed under multi-year engagements, with pricing not publicly disclosed. Reported operational metrics include 2,000+ studies performed over the past five years and 93% on-time report delivery. Strategic partnerships with RSSL (September 2025) and Menarini Biotech (April 2025) extend the offering into GMP analytical services and CMC respectively, and CEO Christophe Priou leads a privately held organization without disclosed external investment or parent ownership.

Name

ERBC

Legal name

EUROPEAN RESEARCH BIOLOGY CENTER

Website

https://erbc-group.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

251–500 employees

Short description

ERBC is a privately held, European preclinical CRO operating six sites in France and Italy, delivering GLP and non-GLP toxicology, safety pharmacology, bioanalysis, NHP supply, and translational research to pharmaceutical, biotech, chemical, cosmetic, and medical device sponsors.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical contract research
• GLP toxicology services
• Safety pharmacology studies
• Drug development CRO
• Non-clinical research services

Headquarters

HQ city

Baugy

HQ country

France

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: ERBC generates revenue through project-based contract research services for preclinical development, including toxicology studies, safety pharmacology, bioanalysis, and translational research. Projects are tailored to client specifications with study design, timelines, and costs defined in proposals.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ERBC is a preclinical Contract Research Organization (CRO) that delivers GLP and non-GLP toxicology, safety pharmacology, bioanalysis, histopathology, PK/PD, and translational research services for pharmaceutical, biotech, chemical, cosmetic, and medical device developers. The company operates six integrated European sites covering discovery through regulatory toxicology, including BSL2/BSL3 laboratories, high-resolution in vivo imaging, and an in-house non-human primate supply chain, to support IND-enabling studies and regulatory submissions.

Product overview

ERBC is a leading preclinical Contract Research Organization (CRO) offering an integrated, end-to-end service portfolio for drug development. The company operates as a unified platform combining multiple specialized services: Discovery Services (including GENESIS due diligence and AVI-PDX avian models), Regulatory Toxicology (GLP/non-GLP), Safety Pharmacology (including non-invasive JET telemetry), Laboratory Sciences (bioanalysis, histopathology, clinical pathology), Clinical Central Laboratory, and NHP Supply. The portfolio was assembled through strategic acquisitions (Voxcan for imaging, OncoFactory for oncology, Novaxia for histopathology, Bioprim for NHP breeding) unified under the ERBC brand in 2025. ERBC serves pharmaceutical, biotech, chemical, agrochemical, cosmetic, and medical device industries with comprehensive preclinical evaluation from early discovery through regulatory submission support.

Differentiator

Problem solved

Functional benefit

Brands

• GENESIS: Scientific due diligence service for drug development projects
• AVI-PDX
• CellDX
• DECRO Telemetry System
• Patholytix

Products and services

• Discovery Services
• Regulatory Toxicology
• Safety Pharmacology
• Laboratory Sciences
• Clinical Central Laboratory
• NHP Supply
• GENESIS

Quantifiable outcome

• 93% of reports delivered before deadlines
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• Reading Scientific Services Ltd (RSSL)flagshipStrategic or Co-development Partner · 16 September 2025Strategic partnership to deliver seamless, end-to-end drug development support. Combines ERBC's excellence in preclinical safety, toxicology, and regulatory science with RSSL's industry-leading GMP analytical capabilities and regulatory consultancy. Creates a cohesive, streamlined offering spanning the full drug development lifecycle from early discovery through to commercialization. With more than 750 scientists across 10 European sites.
• Menarini BiotechcoreStrategic or Co-development Partner · 3 April 2025Strategic partnership to streamline and speed up transition of biopharmaceuticals from research stage to First-In-Human (FIH) clinical trials. Combines ERBC's expertise in non-clinical studies (toxicology, PK, PD, analytics) with Menarini Biotech's CMC capabilities (custom development and manufacturing). Offers efficient development strategies, GLP/GMP quality delivery, and regulatory-ready data through CMC and safety modules to accelerate IND submissions.
• ScendeaminorStrategic or Co-development Partner · 21 March 2025Partnership to unlock safer drug development through complementary expertise. Details available in whitepaper resource on ERBC website.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Charles River Laboratories: Global leader in preclinical CRO services including toxicology, safety pharmacology, and research models. Most direct competitor to ERBC's core GLP toxicology and NHP supply offerings, with substantially broader geographic reach.
• Labcorp Drug Development: Major global CRO offering preclinical toxicology, safety assessment, and central laboratory services. Overlaps directly with ERBC's regulatory toxicology and clinical central laboratory capabilities.
• ICON plc: Global CRO with significant preclinical and clinical capabilities following PRA Health Sciences acquisition. Comparable full-spectrum drug development service provider with strong European presence competing for the same sponsor contracts.
• Inotiv: US-based preclinical CRO and research models provider specializing in toxicology, safety assessment, and animal model supply. Directly comparable to ERBC's GLP toxicology and NHP breeding operations.
• WuXi AppTec: Large global CRO with extensive preclinical toxicology and safety pharmacology capabilities, particularly strong in serving biotech and large pharma sponsors with integrated drug development services.
• Evotec: European CRO offering preclinical ADME, toxicology, and drug discovery services through its Cyprotex and other units. Closely comparable European-based CRO with overlapping discovery and safety pharmacology services.
• Celerion: Mid-size clinical and preclinical CRO specializing in early-stage clinical pharmacology, bioanalysis, and translational research. Comparable in scale and service mix to ERBC's laboratory sciences and translational offerings.

Broad incumbents

• Eurofins Scientific: Large European testing, inspection, and certification conglomerate with pharma/cosmetics/chemical testing services that overlaps with parts of ERBC's chemical and cosmetics safety assessment offerings, though broader in scope.
• SGS Life Sciences: Global testing and certification group with a Life Sciences division offering preclinical and clinical laboratory services. Comparable to ERBC's analytical chemistry, bioanalysis, and central laboratory offerings as part of a much wider testing portfolio.

Emerging players

• Bionova Scientific: US-based preclinical CRO offering analytical, bioanalytical, and lot release services to biopharma. Similar in scale to ERBC and emerging as an integrated alternative for sponsors seeking mid-size CROs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/erbc-group

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ERBC